Kymera Therapeutics KYMR Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Operating margin | -891.1%-335pp | -555.8%-345pp | -210.6%+134pp | -344.4%-206pp | |
| Net margin | -794.1%-318pp | -475.6%-289pp | -187%+144pp | -330.6%-193pp | |
| EBITDA margin | -869.9%-330pp | -540.2%-334pp | -206.1%+132pp | -338%-203pp | |
| Free cash flow margin | -597.7%-157pp | -440.5%-266pp | -174.7%+158pp | -333%-154pp | |
| Returns | |||||
| Return on equity | -25.8%+10.6pp | -36.4%-3.2pp | -33.2%-0.6pp | -32.6%-5.6pp | |
| Return on assets | -22.9%+5.9pp | -28.8%-3.9pp | -24.9%+0.7pp | -25.6%-7.3pp | |
| Return on invested capital | -33.1%+11.4pp | -44.5%-3.7pp | -40.8%-3.8pp | -37%-8.4pp | |
| Efficiency | |||||
| Asset turnover | 0×0.0× | 0.1×-0.1× | 0.1×+0.1× | 0.1×-0.1× | |
| Liquidity | |||||
| Current ratio | 10.5×+2.9× | 7.5×+2.8× | 4.7×-1.1× | 5.9×+1.0× | |
| Quick ratio | 10.5×+2.9× | 7.5×+2.8× | 4.7×-1.1× | 5.9×+1.0× | |
| Cash ratio | 4.3×+2.5× | 1.8×+0.5× | 1.3×+0.3× | 1×+0.4× | |
| Leverage | |||||
| Debt-to-equity | 0.1×-0.1× | 0.1×-0.1× | 0.2×+0.2× | 0×0.0× | |
| Debt-to-assets | 0×0.0× | 0.1×-0.1× | 0.1×+0.1× | 0×0.0× | |
| Per Share | |||||
| Book value per share | $18.70+67.9% | $11.14+64.5% | $6.77-25.5% | $9.09-5.1% | |
| Valuation | |||||
| Market capitalization | $6.22B+139% | $2.61B+74.9% | $1.49B+3.1% | $1.44B-55.9% | |
| Enterprise value | $5.95B+131% | $2.57B+75.6% | $1.47B+5.1% | $1.4B-57.1% | |
| Price / sales | 158.8×+103× | 55.4×+36.4× | 19×-11.9× | 30.9×-14.2× | |
| Price / book | 3.9×+0.8× | 3.1×-0.7× | 3.8×+0.8× | 2.9×-4.2× | |
| EV / sales | 151.8×+97.1× | 54.7×+36.0× | 18.7×-11.1× | 29.8×-14.8× | |
| Free cash flow yield | -3.8%+4.2pp | -8%+1.3pp | -9.2%+1.6pp | -10.8%-6.8pp | |
| Earnings yield | -5%+3.6pp | -8.6%+1.3pp | -9.9%+0.9pp | -10.7%-7.7pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Kymera Therapeutics's ratios come from?
- Every ratio is computed from Kymera Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
